Artiva CEO sells shares to cover tax withholding

Artiva Biotherapeutics, Inc. Chief Executive Officer Fred Aslan reported an open-market sale of 27,116 shares of common stock at a weighted average price of $9.0077 per share.

Rhea-AI Filing Summary

Artiva Biotherapeutics, Inc. Chief Executive Officer Fred Aslan reported an open-market sale of 27,116 shares of common stock at a weighted average price of $9.0077 per share. After this transaction, he directly holds 1,535,082 shares.

The company has a “sell-to-cover” policy for tax withholding on vesting restricted stock units, and these shares were sold automatically to cover related tax obligations, not at Aslan’s discretion. Sale prices ranged between $8.7383 and $9.0104.

Insider Trade Summary

Net Seller: 27,116 shares

Net Sell 1 txn

Insider Aslan Fred

Role Chief Executive Officer

Sold 27,116 shs ($244K)

Type	Security	Shares	Price	Value
Sale	Common Stock	27,116	$9.0077	$244K

Holdings After Transaction: Common Stock — 1,535,082 shares (Direct)

Footnotes (2)

1. F1. The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and release of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.
2. F2. The weighted average sale price for the transaction reported was $9.0077, and the range of prices were between $8.7383 and $9.0104. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

Key Figures

Shares sold: 27,116 shares Weighted average sale price: $9.0077 per share Shares held after transaction: 1,535,082 shares +2 more

5 metrics

Shares sold 27,116 shares Open-market sale on 2026-05-19

Weighted average sale price $9.0077 per share Sell-to-cover transaction

Shares held after transaction 1,535,082 shares Direct holdings following sale

Sale price range low $8.7383 per share Lowest execution price in sale range

Sale price range high $9.0104 per share Highest execution price in sale range

Key Terms

sell-to-cover, restricted stock units, weighted average sale price, Form 4

4 terms

sell-to-cover financial

"The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person."

Sell-to-cover is when part of newly issued or exercised company stock is immediately sold to pay required taxes and fees, so the recipient keeps the remaining shares. For investors this matters because it reduces the number of shares insiders or employees actually hold after a grant, can create small, routine share sales that aren’t signal of cashing out, and slightly increases share supply on the market—like selling a portion of a paycheck to cover the tax bill.

restricted stock units financial

"to cover tax withholding obligations in connection with the vesting and release of restricted stock units."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

weighted average sale price financial

"The weighted average sale price for the transaction reported was $9.0077, and the range of prices were between $8.7383 and $9.0104."

Form 4 regulatory

"The sales reported on this Form 4 represent the number of shares required to be sold"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Artiva Biotherapeutics (ARTV) report for its CEO?

Artiva Biotherapeutics reported that CEO Fred Aslan sold 27,116 shares of common stock. The sale was tied to tax withholding on vesting restricted stock units and executed under the company’s automatic “sell-to-cover” policy, rather than a discretionary open-market trade.

At what price did the Artiva (ARTV) CEO’s sell-to-cover transaction occur?

The CEO’s sell-to-cover transaction had a weighted average sale price of $9.0077 per share. Individual trades occurred within a price range from $8.7383 to $9.0104 per share, reflecting multiple executions to satisfy the required tax withholding amount.

How many Artiva (ARTV) shares does the CEO hold after this Form 4 filing?

Following the reported sale, CEO Fred Aslan directly holds 1,535,082 shares of Artiva common stock. The transaction reduced his holdings only by the 27,116 shares sold to cover tax obligations tied to the vesting and release of restricted stock units.

Was the Artiva (ARTV) CEO’s share sale a discretionary trade?

The sale was not discretionary. Artiva has a “sell-to-cover” policy under which shares are automatically sold to cover tax withholding on vesting restricted stock units, so the number of shares sold and timing were driven by tax requirements, not trading decisions.

Why did Artiva Biotherapeutics (ARTV) adopt a sell-to-cover policy?

Artiva adopted a sell-to-cover policy to satisfy tax withholding obligations when restricted stock units vest for executives. Under this approach, a portion of vested shares is automatically sold in the market, generating cash to meet required payroll tax withholdings efficiently.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/19/2026 - 09:50 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Aslan Fred

(Last) (First) (Middle)

C/O ARTIVA BIOTHERAPEUTICS, INC.

5505 MOREHOUSE DRIVE, SUITE 100

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Artiva Biotherapeutics, Inc. [ ARTV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/19/2026		S		27,116(1)	D	$9.0077(2)	1,535,082	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and release of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

2. The weighted average sale price for the transaction reported was $9.0077, and the range of prices were between $8.7383 and $9.0104. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

	/s/ Andrew Cronauer, Attorney-in-Fact	05/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)